Another Alzheimer's Drug Fails: What Makes This Disease So Tough to Fight?
By Dennis ThompsonHealthDay Reporter
THURSDAY, Jan. 25, 2018 (HealthDay News) -- As more experimental drugs fail to stop Alzheimer's from destroying human memory, experts now wonder whether research into the devastating brain disease has been marching in the wrong direction.
In recent weeks, a pair of high-profile disappointments have been reported, including one just announced on a trial of the Eli Lily drug solanezumab.
Now, researchers are trying to figure out what might have been missed in the search for an Alzheimer's cure.
Did errors occur in the clinical trials of these drugs, creating the failure of potentially promising therapies? Or has there been a fundamental misunderstanding of the complex nature of Alzheimer's disease?
Until now, research has focused mainly on treating or preventing Alzheimer's by attacking the clumps of amyloid beta protein that form in patients' brains, potentially blocking signals sent between brain synapses. Amyloid plaques are one of the hallmarks of the disease.
"The overriding hypothesis for many years has been the amyloid hypothesis -- the idea if you can stop, slow or clear the formation of amyloid plaques from the brain you will be able to treat the disease and see marked improvements in cognition," said James Hendrix, director of global science initiatives for the Alzheimer's Association. "So far, that hasn't worked out."
Solanezumab binds with amyloid beta, and was intended to help the body flush the protein out of the brain before it could form damaging plaques.
But the drug failed to significantly slow thinking declines, Columbia University researchers reported in the Jan. 25 issue of the New England Journal of Medicine.
Those results came on the heels of a trio of failed trials of the drug idalopirdine, which was intended to help treat Alzheimer's by promoting production of serotonin and other essential brain chemicals. A team of researchers reported in the Journal of the American Medical Association earlier this month that the drug failed to improve thinking or memory in Alzheimer's patients.
Are amyloid plaques the wrong target?
During the past decade, Alzheimer's research has focused on amyloid plaques out of financial necessity, Hendrix explained.
"Ten years ago, there was very little funding for Alzheimer's disease," Hendrix said. "When you don't have a lot money for funding, you tend to go for the most obvious approach, and that was amyloid."
But one early hurdle may have tripped up many of the long-term clinical trials that are now coming to fruition, said Dr. Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minn.
Back then, there was no way to tell whether a person diagnosed with Alzheimer's disease actually had amyloid plaques in their brains. These plaques could only be observed during an autopsy.
Scientists now can see amyloid in the brain thanks to PET, an imaging technology that observes metabolic processes in the body. As a result, scientists have learned that about a third of people who appear to have Alzheimer's disease do not have high levels of amyloid in their brains, Hendrix said.
"If 30 percent of the people in your anti-amyloid clinical trial don't have amyloid in their brain, right off the bat your trial is probably going to fail because 30 percent of the people aren't going to respond to your therapeutic," he said.
The basic assumption that removing amyloid will automatically lead to an improvement in Alzheimer's patients needs to be re-evaluated, said Michael Murphy, an associate professor with the University of Kentucky's Sanders-Brown Center on Aging.
Although the genetic evidence has been convincing that amyloid drives the disease, that doesn't mean that removing the protein from people already in the throes of Alzheimer's is going to help them, Murphy said.
"I think really it might be fairer to think that what happens is amyloid pathology is more like a trigger in the disease," he said.
"Once you get that thing going, you can think about it almost like a freight train. You get this going, and it's awfully hard to stop," Murphy said. "You might have removed the trigger, but once you remove the trigger you haven't dealt with the consequences of the events that have been set into motion."
Other factors at play in Alzheimer's
Seniors' brains also are vulnerable to other problems of aging known to contribute to Alzheimer's and dementia, such as high cholesterol and elevated blood pressure, Murphy said.
Whatsapp Group+91 98450 81888
HOME REMEDY IN INDIA
MANGALORE.INDIA
Think Good Do Good
Pl send name and place for joining whatsapp Group
__._,_.___
Posted by: =?UTF-8?Q?=E2=99=A3_=E2=99=A3_=E2=99=A3M=2ED=2E_?= =?UTF-8?Q?HEGDE=E2=99=A3_=E2=99=A3_=E2=99=A3?= <hegde_csl@yahoo.co.in>
| Reply via web post | • | Reply to sender | • | Reply to group | • | Start a New Topic | • | Messages in this topic (1) |
Have you tried the highest rated email app?
With 4.5 stars in iTunes, the Yahoo Mail app is the highest rated email app on the market. What are you waiting for? Now you can access all your inboxes (Gmail, Outlook, AOL and more) in one place. Never delete an email again with 1000GB of free cloud storage.
KERALITES - A moderated eGroup exclusively for Keralites...
To subscribe send a mail to Keralites-subscribe@yahoogroups.com.
Send your posts to Keralites@yahoogroups.com.
Send your suggestions to Keralites-owner@yahoogroups.com.
To unsubscribe send a mail to Keralites-unsubscribe@yahoogroups.com.
Homepage: http://www.keralites.net
To subscribe send a mail to Keralites-subscribe@yahoogroups.com.
Send your posts to Keralites@yahoogroups.com.
Send your suggestions to Keralites-owner@yahoogroups.com.
To unsubscribe send a mail to Keralites-unsubscribe@yahoogroups.com.
Homepage: http://www.keralites.net
.
__,_._,___
